• TNI BioTech Products

    IRT-101 is an active immunotherapy that works by activating a patient's immune system against infectious diseases and tumor cells
    +Read More
  • Our Approach

    The purpose of TNI BioTech's immunotherapy is to increase the production of the immune system by increasing production of DC cells...
    +Read More
  • Business Development

    TNI BioTech has acquired a number of patents and is in planning on the commercialization of our patented technology.
    +Read More
  • 1
  • 2
  • 3
Follow Us

2014 Shareholder Meeting

Read the 2014 Shareholder Meeting Agenda and Transcript Read Now

Letter of Instruction to Broker

Download Letter of Instruction to Broker to Transfer Stock Download

Company Overview

At TNI BioTech, Inc., our goal is to benefit patients with chronic and often life-threatening diseases through the activation and rebalancing of the body's immune system using our patented immunotherapy.

Our products, technologies, and patents are designed to harness the power of the immune system to improve the treatment of cancer and infections, such as HIV/AIDS and autoimmune diseases. We are currently developing active and adoptive forms of immunotherapies.

Our most advanced clinical programs involve immunotherapy with methionine-enkephalin (MENK) or low dose naltrexone, which both work by triggering opioid receptors on immune cells and lead to an activation and expansion of various cells in the immune system.

OneMedPlace Management Interview: Noreen McGurrin Griffin, CEO of TNI Biotech

* This video was published in January 2013. The information contained in this video speaks only as of January 2013, and TNI BioTech, Inc. has, and accepts, no responsibility or duty to update any such information and reserves the right to add to, remove or amend any information contained in this video. This video may contain projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon expectations as of the date of this video and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more specifically identified in our most recent Securities and Exchange Commission filings. Although we may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.



 is an active immunotherapy that works by activating a patient's immune system against infectious diseases and tumor cells.

Read More



is an adaptive immunotherapy that works by isolating and enriching a patient's own immune cells and following an enriching external incubation...

Read More


IRT- 103 

is an active immunotherapy that works by activating a patient's immune system against HIV/AIDS and tumor cells.

Read More

Latest News

Effects of the enkephalins on natural killer cytotoxicity

Dec 12 1990

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 1990 Dec;12(6):457-60.

[Effects of the enkephalins on natural killer cytotoxicity].
[Article in Chinese]
Lin J.

Institute of Basic Medical Sciences, Beijing.


Spleen mononuclear cells of BALB/C mice and YAC-1 cells were used in this experiment.

Leucine enkephalin or methionine enkephalin at time 0 was added to cell cultures and the amount of the enzyme lactate dehydrogenase released from lysed target cells was determined 22 hours after incubation. There were on average 41% (5% to 60.7%) and 63% (46.8% to 78%) enhancements of natural killer activity in the presence of leucine enkephalin (1 x 10(-11)-1 x 10(-3) mg/ml) and methionine enkephalin (1 x 10(-15)-1 x 10(-3) mg/ml) respectively. The results showed that opioid peptides can modify NK cell function.